Reactive oxygen species in cardiovascular disease

Free Radical Biology and Medicine

Volumn 51, Issue 5, 2011, Pages 978-992

  Sugamura, Koichi ^a   Keaney Jr , John F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Cardiovascular disease; Clinical trials; Free radicals; Reactive oxygen species

Indexed keywords

ABC TRANSPORTER A1; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BILIRUBIN; BIOLOGICAL MARKER; BIOPYRRINS; CELL DNA; DEFEROXAMINE; GLUTATHIONE PEROXIDASE 1; ISOPROSTANE DERIVATIVE; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; NORPHENAZONE; OXIPURINOL; PEROXIREDOXIN 3; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUCCINOBUCOL; UBIDECARENONE; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAPILLARY LEAK SYNDROME; CARDIAC PATIENT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL MIGRATION; CHRONIC GRANULOMATOUS DISEASE; CONGESTIVE HEART FAILURE; ELECTROCARDIOGRAM; ELECTRON TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HEREDITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITRAL VALVE REGURGITATION; MUSCLE ATROPHY; OUTCOME ASSESSMENT; OXIDATION; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTMENOPAUSE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; REOXYGENATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HEART; HUMANS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 80051666038     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.05.004     Document Type: Review

References (298)

1. D. Harman Aging: a theory based on free radical and radiation chemistry J. Gerontol. 11 1956 298 300
2. J.E. Enstrom, L.E. Kanim, and M.A. Klein Vitamin C intake and mortality among a sample of the United States population Epidemiology 3 1992 194 202
3. K.T. Khaw, S. Bingham, A. Welch, R. Luben, N. Wareham, S. Oakes, and N. Day Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition Lancet 357 2001 657 663 (Pubitemid 32206423)
4. K. Nyyssonen, M.T. Parviainen, R. Salonen, J. Tuomilehto, and J.T. Salonen Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland BMJ 314 1997 634 638 (Pubitemid 27099877)
5. S.K. Osganian, M.J. Stampfer, E. Rimm, D. Spiegelman, F.B. Hu, J.E. Manson, and W.C. Willett Vitamin C and risk of coronary heart disease in women J. Am. Coll. Cardiol. 42 2003 246 252 (Pubitemid 36851413)
6. M.J. Stampfer, C.H. Hennekens, J.E. Manson, G.A. Colditz, B. Rosner, and W.C. Willett Vitamin E consumption and the risk of coronary disease in women N. Engl. J. Med. 328 1993 1444 1449 (Pubitemid 23143846)
7. E.B. Rimm, M.J. Stampfer, A. Ascherio, E. Giovannucci, G.A. Colditz, and W.C. Willett Vitamin E consumption and the risk of coronary heart disease in men N. Engl. J. Med. 328 1993 1450 1456 (Pubitemid 23143847)
8. C.R. Gale, C.N. Martyn, P.D. Winter, and C. Cooper Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people BMJ 310 1995 1563 1566
9. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 23 33
10. H.D. Sesso, J.E. Buring, W.G. Christen, T. Kurth, C. Belanger, J. MacFadyen, V. Bubes, J.E. Manson, R.J. Glynn, and J.M. Gaziano Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial JAMA 300 2008 2123 2133
11. L.H. Kushi, A.R. Folsom, R.J. Prineas, P.J. Mink, Y. Wu, and R.M. Bostick Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women N. Engl. J. Med. 334 1996 1156 1162 (Pubitemid 26137974)
12. K.G. Losonczy, T.B. Harris, and R.J. Havlik Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly Am. J. Clin. Nutr. 64 1996 190 196 (Pubitemid 26250838)
13. J. Virtamo, J.M. Rapola, S. Ripatti, O.P. Heinonen, P.R. Taylor, D. Albanes, and J.K. Huttunen Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease Arch. Intern. Med. 158 1998 668 675 (Pubitemid 28144826)
14. G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project Lancet 357 2001 89 95
15. I.M. Lee, N.R. Cook, J.M. Gaziano, D. Gordon, P.M. Ridker, J.E. Manson, C.H. Hennekens, and J.E. Buring Vitamin E in the primary prevention of cardiovascular disease and cancer. The Women's Health Study: a randomized controlled trial JAMA 294 2005 56 65 (Pubitemid 41002839)
16. S. Yusuf, G. Dagenais, J. Pogue, J. Bosch, and P. Sleight Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N. Engl. J. Med. 342 2000 154 160 (Pubitemid 30051646)
17. E. Lonn, J. Bosch, S. Yusuf, P. Sheridan, J. Pogue, J.M. Arnold, C. Ross, A. Arnold, P. Sleight, J. Probstfield, and G.R. Dagenais Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial JAMA 293 2005 1338 1347 (Pubitemid 40381486)
18. G.S. Omenn, G.E. Goodman, M.D. Thornquist, J. Balmes, M.R. Cullen, A. Glass, J.P. Keogh, F.L. Meyskens, B. Valanis, J.H. Williams, S. Barnhart, and S. Hammar Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N. Engl. J. Med. 334 1996 1150 1155 (Pubitemid 26137973)
19. C.H. Hennekens, J.E. Buring, J.E. Manson, M. Stampfer, B. Rosner, N.R. Cook, C. Belanger, F. LaMotte, J.M. Gaziano, P.M. Ridker, W. Willett, and R. Peto Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease N. Engl. J. Med. 334 1996 1145 1149 (Pubitemid 26137972)
20. I.M. Lee, N.R. Cook, J.E. Manson, J.E. Buring, and C.H. Hennekens Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study J. Natl. Cancer Inst. 91 1999 2102 2106 (Pubitemid 30019571)
21. D.D. Waters, E.L. Alderman, J. Hsia, B.V. Howard, F.R. Cobb, W.J. Rogers, P. Ouyang, P. Thompson, J.C. Tardif, L. Higginson, V. Bittner, M. Steffes, D.J. Gordon, M. Proschan, N. Younes, and J.I. Verter Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial JAMA 288 2002 2432 2440 (Pubitemid 35340539)
22. N.R. Cook, C.M. Albert, J.M. Gaziano, E. Zaharris, J. MacFadyen, E. Danielson, J.E. Buring, and J.E. Manson A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study Arch. Intern. Med. 167 2007 1610 1618 (Pubitemid 47280341)
23. N.G. Stephens, A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseman, and M.J. Mitchinson Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 347 1996 781 786 (Pubitemid 26091640)
24. M. Boaz, S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru, and M.S. Green Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial Lancet 356 2000 1213 1218
25. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 1999 447 455
26. J.M. Rapola, J. Virtamo, S. Ripatti, J.K. Haukka, J.K. Huttunen, D. Albanes, P.R. Taylor, and O.P. Heinonen Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris Heart 79 1998 454 458 (Pubitemid 28215823)
27. J.M. Rapola, J. Virtamo, S. Ripatti, J.K. Huttunen, D. Albanes, P.R. Taylor, and O.P. Heinonen Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction Lancet 349 1997 1715 1720 (Pubitemid 27252669)
28. D.P. Vivekananthan, M.S. Penn, S.K. Sapp, A. Hsu, and E.J. Topol Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials Lancet 361 2003 2017 2023 (Pubitemid 36695043)
29. T.J. Anderson, I.T. Meredith, A.C. Yeung, B. Frei, A.P. Selwyn, and P. Ganz The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion N. Engl. J. Med. 332 1995 488 493
30. J.F. Keaney Jr., A. Xu, D. Cunningham, T. Jackson, B. Frei, and J.A. Vita Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation J. Clin. Invest. 95 1995 2520 2529
31. S. Parthasarathy, S.G. Young, J.L. Witztum, R.C. Pittman, and D. Steinberg Probucol inhibits oxidative modification of low density lipoprotein J. Clin. Invest. 77 1986 641 644 (Pubitemid 16037669)
32. J.C. Tardif, G. Cote, J. Lesperance, M. Bourassa, J. Lambert, S. Doucet, L. Bilodeau, S. Nattel, and P. de Guise Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group N. Engl. J. Med. 337 1997 365 372 (Pubitemid 27328366)
33. H. Daida, Y. Kuwabara, H. Yokoi, H. Nishikawa, F. Takatsu, Y. Nakata, Y. Kutsumi, S. Oshima, S. Nishiyama, S. Ishiwata, K. Kato, S. Nishimura, K. Miyauchi, T. Kanoh, and H. Yamaguchi Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial (PART)) Am. J. Cardiol. 86 2000 550 552 (A559)
34. H. Yokoi, H. Daida, Y. Kuwabara, H. Nishikawa, F. Takatsu, H. Tomihara, Y. Nakata, Y. Kutsumi, S. Ohshima, S. Nishiyama, A. Seki, K. Kato, S. Nishimura, T. Kanoh, and H. Yamaguchi Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial J. Am. Coll. Cardiol. 30 1997 855 862 (Pubitemid 27435873)
35. F. Walldius, U. Erikson, A.G. Olsson, L. Bergstrand, K. Hadell, J. Johansson, L. Kaijser, C. Lassvik, J. Molgaard, and S. Nillson The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST) Am. J. Cardiol. 74 1994 875 883 (Pubitemid 24340308)
36. S. Parthasarathy Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein: use of a new water-soluble probucol derivative J. Clin. Invest. 89 1992 1618 1621
37. J.C. Tardif, J.J. McMurray, E. Klug, R. Small, J. Schumi, J. Choi, J. Cooper, R. Scott, E.F. Lewis, P.L. L'Allier, and M.A. Pfeffer Effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled trial Lancet 371 2008 1761 1768 (Pubitemid 351697951)
38. B. Halliwell, J. Rafter, and A. Jenner Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am. J. Clin. Nutr. 81 2005 268S 276S
39. M.G. Traber, B. Frei, and J.S. Beckman Vitamin E revisited: do new data validate benefits for chronic disease prevention? Curr. Opin. Lipidol. 19 2008 30 38
40. D. Steinberg The LDL modification hypothesis of atherogenesis: an update J. Lipid Res. 50 2009 S376 S381 (Suppl.)
41. B. Halliwell The wanderings of a free radical Free Radic. Biol. Med. 46 2009 531 542
42. U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, S. Keidar, Y. Levy, A. Khemlin, A. Radan, and A.P. Levy Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial Arterioscler. Thromb. Vasc. Biol. 28 2008 341 347 (Pubitemid 351161209)
43. J.M. Zingg, A. Azzi, and M. Meydani Genetic polymorphisms as determinants for disease-preventive effects of vitamin E Nutr. Rev. 66 2008 406 414 (Pubitemid 352000151)
44. J.A. Leopold, and J. Loscalzo Oxidative enzymopathies and vascular disease Arterioscler. Thromb. Vasc. Biol. 25 2005 1332 1340
45. J.F. Keaney Jr., M.G. Larson, R.S. Vasan, P.W. Wilson, I. Lipinska, D. Corey, J.M. Massaro, P. Sutherland, J.A. Vita, and E.J. Benjamin Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study Arterioscler. Thromb. Vasc. Biol. 23 2003 434 439 (Pubitemid 36337219)
46. T. Finkel, and N.J. Holbrook Oxidants, oxidative stress and the biology of ageing Nature 408 2000 239 247
47. R. Stocker, and J.F. Keaney Jr. Role of oxidative modifications in atherosclerosis Physiol. Rev. 84 2004 1381 1478 (Pubitemid 39302636)
48. B. Chance, H. Sies, and A. Boveris Hydroperoxide metabolism in mammalian organs Physiol. Rev. 59 1979 527 605 (Pubitemid 9236599)
49. Y. Li, T.T. Huang, E.J. Carlson, S. Melov, P.C. Ursell, J.L. Olson, L.J. Noble, M.P. Yoshimura, C. Berger, P.H. Chan, D.C. Wallace, and C.J. Epstein Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase Nat. Genet. 11 1995 376 381
50. H. Nojiri, T. Shimizu, M. Funakoshi, O. Yamaguchi, H. Zhou, S. Kawakami, Y. Ohta, M. Sami, T. Tachibana, H. Ishikawa, H. Kurosawa, R.C. Kahn, K. Otsu, and T. Shirasawa Oxidative stress causes heart failure with impaired mitochondrial respiration J. Biol. Chem. 281 2006 33789 33801 (Pubitemid 46036756)
51. S. Matsushima, T. Ide, M. Yamato, H. Matsusaka, F. Hattori, M. Ikeuchi, T. Kubota, K. Sunagawa, Y. Hasegawa, T. Kurihara, S. Oikawa, S. Kinugawa, and H. Tsutsui Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice Circulation 113 2006 1779 1786 (Pubitemid 43958471)
52. K. Bedard, and K.H. Krause The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology Physiol. Rev. 87 2007 245 313 (Pubitemid 46209993)
53. K. Chen, S.E. Craige, and J.F. Keaney Jr. Downstream targets and intracellular compartmentalization in Nox signaling Antioxid. Redox Signal. 11 2009 2467 2480
54. S. Johar, A.C. Cave, A. Narayanapanicker, D.J. Grieve, and A.M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J. 20 2006 1546 1548
55. R.M. Bell, A.C. Cave, S. Johar, D.J. Hearse, A.M. Shah, and M.J. Shattock Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning FASEB J. 19 2005 2037 2039 (Pubitemid 41759757)
56. Y.H. Looi, D.J. Grieve, A. Siva, S.J. Walker, N. Anilkumar, A.C. Cave, M. Marber, M.J. Monaghan, and A.M. Shah Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction Hypertension 51 2008 319 325 (Pubitemid 351159945)
57. M. Satoh, H. Ogita, K. Takeshita, Y. Mukai, D.J. Kwiatkowski, and J.K. Liao Requirement of Rac1 in the development of cardiac hypertrophy Proc. Natl. Acad. Sci. U. S. A. 103 2006 7432 7437 (Pubitemid 43727850)
58. J.A. Byrne, D.J. Grieve, J.K. Bendall, J.M. Li, C. Gove, J.D. Lambeth, A.C. Cave, and A.M. Shah Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy Circ. Res. 93 2003 802 805
59. J.K. Bendall, A.C. Cave, C. Heymes, N. Gall, and A.M. Shah Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice Circulation 105 2002 293 296 (Pubitemid 34106175)
60. M. Maytin, D.A. Siwik, M. Ito, L. Xiao, D.B. Sawyer, R. Liao, and W.S. Colucci Pressure overload-induced myocardial hypertrophy in mice does not require gp91phox Circulation 109 2004 1168 1171 (Pubitemid 38332622)
61. P.A. Barry-Lane, C. Patterson, M. van der Merwe, Z. Hu, S.M. Holland, E.T. Yeh, and M.S. Runge p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice J. Clin. Invest. 108 2001 1513 1522 (Pubitemid 33091989)
62. A.E. Vendrov, Z.S. Hakim, N.R. Madamanchi, M. Rojas, C. Madamanchi, and M.S. Runge Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells Arterioscler. Thromb. Vasc. Biol. 27 2007 2714 2721 (Pubitemid 350158927)
63. C.P. Judkins, H. Diep, B.R. Broughton, A.E. Mast, E.U. Hooker, A.A. Miller, S. Selemidis, G.J. Dusting, C.G. Sobey, and G.R. Drummond Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice Am. J. Physiol. Heart Circ. Physiol. 298 2009 H24 H32
64. M. Thomas, D. Gavrila, M.L. McCormick, F.J. Miller Jr., A. Daugherty, L.A. Cassis, K.C. Dellsperger, and N.L. Weintraub Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice Circulation 114 2006 404 413 (Pubitemid 44264822)
65. Z. Chen, J.F. Keaney Jr., E. Schulz, B. Levison, L. Shan, M. Sakuma, X. Zhang, C. Shi, S.L. Hazen, and D.I. Simon Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury Proc. Natl. Acad. Sci. U. S. A. 101 2004 13014 13019 (Pubitemid 39167575)
66. M. Ushio-Fukai Compartmentalization of redox signaling through NADPH oxidase-derived ROS Antioxid. Redox Signal. 11 2009 1289 1299
67. E.D. Jarasch, C. Grund, G. Bruder, H.W. Heid, T.W. Keenan, and W.W. Franke Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium Cell 25 1981 67 82 (Pubitemid 11087436)
68. R. Harrison Structure and function of xanthine oxidoreductase: where are we now? Free Radic. Biol. Med. 33 2002 774 797 (Pubitemid 35232313)
69. E. Della Corte, G. Gozzetti, F. Novello, and F. Stirpe Properties of the xanthine oxidase from human liver Biochim. Biophys. Acta 191 1969 164 166
70. D.N. Granger, M.E. Hollwarth, and D.A. Parks Ischemia-reperfusion injury: role of oxygen-derived free radicals Acta Physiol. Scand. Suppl. 548 1986 47 63 (Pubitemid 16090298)
71. D.N. Granger, G. Rutili, and J.M. McCord Superoxide radicals in feline intestinal ischemia Gastroenterology 81 1981 22 29 (Pubitemid 11078477)
72. J.M. McCord Oxygen-derived free radicals in postischemic tissue injury N. Engl. J. Med. 312 1985 159 163 (Pubitemid 15192863)
73. T. Ohtsubo, I.I. Rovira, M.F. Starost, C. Liu, and T. Finkel Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2 Circ. Res. 95 2004 1118 1124 (Pubitemid 39557899)
74. P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol Pharmacol. Rev. 58 2006 87 114
75. K. Schroder, C. Vecchione, O. Jung, J.G. Schreiber, R. Shiri-Sverdlov, P.J. van Gorp, R. Busse, and R.P. Brandes Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet Free Radic. Biol. Med. 41 2006 1353 1360 (Pubitemid 44479882)
76. T.M. Millar, C.R. Stevens, N. Benjamin, R. Eisenthal, R. Harrison, and D.R. Blake Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions FEBS Lett. 427 1998 225 228 (Pubitemid 28225062)
77. H. Li, A. Samouilov, X. Liu, and J.L. Zweier Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues Biochemistry 42 2003 1150 1159 (Pubitemid 36159550)
78. Z. Zhang, D. Naughton, P.G. Winyard, N. Benjamin, D.R. Blake, and M.C. Symons Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity Biochem. Biophys. Res. Commun. 249 1998 767 772 (Pubitemid 28441913)
79. B.L. Godber, J.J. Doel, G.P. Sapkota, D.R. Blake, C.R. Stevens, R. Eisenthal, and R. Harrison Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase J. Biol. Chem. 275 2000 7757 7763 (Pubitemid 30159680)
80. J.S. McNally, M.E. Davis, D.P. Giddens, A. Saha, J. Hwang, S. Dikalov, H. Jo, and D.G. Harrison Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress Am. J. Physiol. Heart Circ. Physiol. 285 2003 H2290 H2297
81. U. Landmesser, S. Spiekermann, C. Preuss, S. Sorrentino, D. Fischer, C. Manes, M. Mueller, and H. Drexler Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease Arterioscler. Thromb. Vasc. Biol. 27 2007 943 948 (Pubitemid 46606729)
82. A.R. Brash Lipoxygenases occurrence, functions, catalysis, and acquisition of substrate J. Biol. Chem. 274 1999 23679 23682
83. N. Kuhn, D. Heydeck, I. Hugou, and C. Gniwotta In vivo action of 15-lipoxygenase in early stages of human atherosclerosis J. Clin. Invest. 99 1997 888
84. L. Zhao, and C.D. Funk Lipoxygenase pathways in atherogenesis Trends Cardiovasc. Med. 14 2004 191 195 (Pubitemid 38942827)
85. K. Lotzer, C.D. Funk, and A.J. Habenicht The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis Biochim. Biophys. Acta 1736 2005 30 37 (Pubitemid 41208257)
86. H. Kuhn, and V.B. O'Donnell Inflammation and immune regulation by 12/15-lipoxygenases Prog. Lipid Res. 45 2006 334 356 (Pubitemid 43818131)
87. T. Cyrus, D. Pratico, L. Zhao, J.L. Witztum, D.J. Rader, J. Rokach, G.A. FitzGerald, and C.D. Funk Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice Circulation 103 2001 2277 2282 (Pubitemid 32433718)
88. T. Cyrus, J.L. Witztum, D.J. Rader, R. Tangirala, S. Fazio, M.F. Linton, and C.D. Funk Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice J. Clin. Invest. 103 1999 1597 1604
89. J. George, A. Afek, A. Shaish, H. Levkovitz, N. Bloom, T. Cyrus, L. Zhao, C.D. Funk, E. Sigal, and D. Harats 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice Circulation 104 2001 1646 1650 (Pubitemid 32947528)
90. M. Mehrabian, H. Allayee, J. Wong, W. Shi, X.P. Wang, Z. Shaposhnik, C.D. Funk, and A.J. Lusis Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice Circ. Res. 91 2002 120 126 (Pubitemid 34827222)
91. L. Zhao, C.A. Cuff, E. Moss, U. Wille, T. Cyrus, E.A. Klein, D. Pratico, D.J. Rader, C.A. Hunter, E. Pure, and C.D. Funk Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia J. Biol. Chem. 277 2002 35350 35356
92. D.T. Bolick, A.W. Orr, A. Whetzel, S. Srinivasan, M.E. Hatley, M.A. Schwartz, and C.C. Hedrick 12/15-Lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB Arterioscler. Thromb. Vasc. Biol. 25 2005 2301 2307 (Pubitemid 41552646)
93. K.B. Reilly, S. Srinivasan, M.E. Hatley, M.K. Patricia, J. Lannigan, D.T. Bolick, G. Vandenhoff, H. Pei, R. Natarajan, J.L. Nadler, and C.C. Hedrick 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo J. Biol. Chem. 279 2004 9440 9450 (Pubitemid 38296011)
94. D.T. Bolick, S. Srinivasan, A. Whetzel, L.C. Fuller, and C.C. Hedrick 12/15 Lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NF-kappaB Arterioscler. Thromb. Vasc. Biol. 26 2006 1260 1266 (Pubitemid 44305368)
95. J.H. Dwyer, H. Allayee, K.M. Dwyer, J. Fan, H. Wu, R. Mar, A.J. Lusis, and M. Mehrabian Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis N. Engl. J. Med. 350 2004 29 37 (Pubitemid 38032181)
96. R. Spanbroek, R. Grabner, K. Lotzer, M. Hildner, A. Urbach, K. Ruhling, M.P. Moos, B. Kaiser, T.U. Cohnert, T. Wahlers, A. Zieske, G. Plenz, H. Robenek, P. Salbach, H. Kuhn, O. Radmark, B. Samuelsson, and A.J. Habenicht Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis Proc. Natl. Acad. Sci. U. S. A. 100 2003 1238 1243 (Pubitemid 36183986)
97. F. Cipollone, A. Mezzetti, M.L. Fazia, C. Cuccurullo, A. Iezzi, S. Ucchino, F. Spigonardo, M. Bucci, F. Cuccurullo, S.M. Prescott, and D.M. Stafforini Association between 5-lipoxygenase expression and plaque instability in humans Arterioscler. Thromb. Vasc. Biol. 25 2005 1665 1670 (Pubitemid 41098938)
98. X. Houard, V. Ollivier, L. Louedec, J.B. Michel, and M. Back Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus FASEB J. 23 2009 1376 1383
99. J.C. Tardif, P.L. L'Allier, R. Ibrahim, J.C. Gregoire, A. Nozza, M. Cossette, S. Kouz, M.A. Lavoie, J. Paquin, T.M. Brotz, R. Taub, and J. Pressacco Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome Circ. Cardiovasc. Imaging 3 2010 298 307
100. H. Hakonarson, S. Thorvaldsson, A. Helgadottir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D.O. Arnar, K. Andersen, A. Sigurdsson, G. Thorgeirsson, A. Jonsson, U. Agnarsson, H. Bjornsdottir, G. Gottskalksson, A. Einarsson, H. Gudmundsdottir, A.E. Adalsteinsdottir, K. Gudmundsson, K. Kristjansson, T. Hardarson, A. Kristinsson, E.J. Topol, J. Gulcher, A. Kong, M. Gurney, G. Thorgeirsson, and K. Stefansson Effects of a 5-lipoxygenase- activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial JAMA 293 2005 2245 2256 (Pubitemid 40629191)
101. W.K. Alderton, C.E. Cooper, and R.G. Knowles Nitric oxide synthases: structure, function and inhibition Biochem. J. 357 2001 593 615 (Pubitemid 32735142)
102. O.W. Griffith, and D.J. Stuehr Nitric oxide synthases: properties and catalytic mechanism Annu. Rev. Physiol. 57 1995 707 736
103. S.P. Janssens, A. Simouchi, T. Quertermous, D.B. Bloch, and K.D. Bloch Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase J. Biol. Chem. 267 1992 22964 22967
104. J. Vasquez-Vivar, B. Kalyanaraman, P. Martasek, N. Hogg, B.S. Masters, H. Karoui, P. Tordo, and K.A. Pritchard Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors Proc. Natl. Acad. Sci. U. S. A. 95 1998 9220 9225 (Pubitemid 28506212)
105. J.E. Freedman, L. Li, R. Sauter, and J.J. Keaney alpha-Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release FASEB J. 14 2000 2377 2379
106. J.B. Laursen, M. Somers, S. Kurz, L. McCann, A. Warnholtz, B.A. Freeman, M. Tarpey, T. Fukai, and D.G. Harrison Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin Circulation 103 2001 1282 1288 (Pubitemid 32221353)
107. T.J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai, and K.M. Channon Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase Circulation 105 2002 1656 1662 (Pubitemid 34298608)
108. C. Antoniades, C. Shirodaria, P. Leeson, A. Antonopoulos, N. Warrick, T. Van-Assche, C. Cunnington, D. Tousoulis, R. Pillai, C. Ratnatunga, C. Stefanadis, and K.M. Channon Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis Eur. Heart J. 30 2009 1142 1150
109. M.C. Verhaar, R.M. Wever, J.J. Kastelein, T. van Dam, H.A. Koomans, and T.J. Rabelink 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia Circulation 97 1998 237 241 (Pubitemid 28067307)
110. J.M. Armitage, L. Bowman, R.J. Clarke, K. Wallendszus, R. Bulbulia, K. Rahimi, R. Haynes, S. Parish, P. Sleight, R. Peto, and R. Collins Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial JAMA 303 2010 2486 2494
111. C. Antoniades, C. Shirodaria, N. Warrick, S. Cai, J. de Bono, J. Lee, P. Leeson, S. Neubauer, C. Ratnatunga, R. Pillai, H. Refsum, and K.M. Channon 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling Circulation 114 2006 1193 1201 (Pubitemid 44386484)
112. C. Antoniades, C. Shirodaria, P. Leeson, O.A. Baarholm, T. Van-Assche, C. Cunnington, R. Pillai, C. Ratnatunga, D. Tousoulis, C. Stefanadis, H. Refsum, and K.M. Channon MTHFR 677 C > T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis Circulation 119 2009 2507 2515
113. P.J. Kuhlencordt, R. Gyurko, F. Han, M. Scherrer-Crosbie, T.H. Aretz, R. Hajjar, M.H. Picard, and P.L. Huang Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice Circulation 104 2001 448 454 (Pubitemid 32678276)
114. M. Ozaki, S. Kawashima, T. Yamashita, T. Hirase, M. Namiki, N. Inoue, K. Hirata, H. Yasui, H. Sakurai, Y. Yoshida, M. Masada, and M. Yokoyama Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice J. Clin. Invest. 110 2002 331 340 (Pubitemid 34847965)
115. J.K. Bendall, N.J. Alp, N. Warrick, S. Cai, D. Adlam, K. Rockett, M. Yokoyama, S. Kawashima, and K.M. Channon Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression Circ. Res. 97 2005 864 871 (Pubitemid 41552671)
116. N.J. Alp, M.A. McAteer, J. Khoo, R.P. Choudhury, and K.M. Channon Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice Arterioscler. Thromb. Vasc. Biol. 24 2004 445 450 (Pubitemid 38326136)
117. T. Takaya, K. Hirata, T. Yamashita, M. Shinohara, N. Sasaki, N. Inoue, T. Yada, M. Goto, A. Fukatsu, T. Hayashi, N.J. Alp, K.M. Channon, M. Yokoyama, and S. Kawashima A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression Arterioscler. Thromb. Vasc. Biol. 27 2007 1632 1637 (Pubitemid 46986120)
118. M. Scherrer-Crosbie, R. Ullrich, K.D. Bloch, H. Nakajima, B. Nasseri, H.T. Aretz, M.L. Lindsey, A.C. Vancon, P.L. Huang, R.T. Lee, W.M. Zapol, and M.H. Picard Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice Circulation 104 2001 1286 1291 (Pubitemid 32848119)
119. F. Ichinose, K.D. Bloch, J.C. Wu, R. Hataishi, H.T. Aretz, M.H. Picard, and M. Scherrer-Crosbie Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency Am. J. Physiol. Heart Circ. Physiol. 286 2004 H1070 H1075
120. S.P. Jones, J.J. Greer, R. van Haperen, D.J. Duncker, R. de Crom, and D.J. Lefer Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice Proc. Natl. Acad. Sci. U. S. A. 100 2003 4891 4896 (Pubitemid 36457824)
121. S.P. Jones, J.J. Greer, A.K. Kakkar, P.D. Ware, R.H. Turnage, M. Hicks, R. van Haperen, R. de Crom, S. Kawashima, M. Yokoyama, and D.J. Lefer Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury Am. J. Physiol. Heart Circ. Physiol. 286 2004 H276 H282
122. S. Janssens, P. Pokreisz, L. Schoonjans, M. Pellens, P. Vermeersch, M. Tjwa, P. Jans, M. Scherrer-Crosbie, M.H. Picard, Z. Szelid, H. Gillijns, F. Van de Werf, D. Collen, and K.D. Bloch Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction Circ. Res. 94 2004 1256 1262 (Pubitemid 38656413)
123. E.S. Buys, M.J. Raher, S.L. Blake, T.G. Neilan, A.R. Graveline, J.J. Passeri, M. Llano, T.M. Perez-Sanz, F. Ichinose, S. Janssens, W.M. Zapol, M.H. Picard, K.D. Bloch, and M. Scherrer-Crosbie Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload Am. J. Physiol. Heart Circ. Physiol. 293 2007 H620 H627
124. A.L. Moens, E. Takimoto, C.G. Tocchetti, K. Chakir, D. Bedja, G. Cormaci, E.A. Ketner, M. Majmudar, K. Gabrielson, M.K. Halushka, J.B. Mitchell, S. Biswal, K.M. Channon, M.S. Wolin, N.J. Alp, N. Paolocci, H.C. Champion, and D.A. Kass Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy Circulation 117 2008 2626 2636
125. T. Miyoshi, Y. Li, D.M. Shih, X. Wang, V.E. Laubach, A.H. Matsumoto, G.A. Helm, A.J. Lusis, and W. Shi Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice Life Sci. 79 2006 525 531
126. P.A. Detmers, M. Hernandez, J. Mudgett, H. Hassing, C. Burton, S. Mundt, S. Chun, D. Fletcher, D.J. Card, J. Lisnock, R. Weikel, J.D. Bergstrom, D.E. Shevell, A. Hermanowski-Vosatka, C.P. Sparrow, Y.S. Chao, D.J. Rader, S.D. Wright, and E. Pure Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice J. Immunol. 165 2000 3430 3435
127. P.J. Kuhlencordt, J. Chen, F. Han, J. Astern, and P.L. Huang Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice Circulation 103 2001 3099 3104 (Pubitemid 32587858)
128. Q. Feng, X. Lu, D.L. Jones, J. Shen, and J.M. Arnold Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice Circulation 104 2001 700 704 (Pubitemid 32738526)
129. P. Zhang, X. Xu, X. Hu, E.D. van Deel, G. Zhu, and Y. Chen Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure Circ. Res. 100 2007 1089 1098 (Pubitemid 46598934)
130. I.N. Mungrue, R. Gros, X. You, A. Pirani, A. Azad, T. Csont, R. Schulz, J. Butany, D.J. Stewart, and M. Husain Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death J. Clin. Invest. 109 2002 735 743 (Pubitemid 34263150)
131. C.A. Gunnett, D.D. Lund, A.K. McDowell, F.M. Faraci, and D.D. Heistad Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction Arterioscler. Thromb. Vasc. Biol. 25 2005 1617 1622 (Pubitemid 41098930)
132. P.J. Kuhlencordt, S. Hotten, J. Schodel, S. Rutzel, K. Hu, J. Widder, A. Marx, P.L. Huang, and G. Ertl Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein E knockout mice Arterioscler. Thromb. Vasc. Biol. 26 2006 1539 1544 (Pubitemid 44288980)
133. S.A. Khan, K. Lee, K.M. Minhas, D.R. Gonzalez, S.V. Raju, A.D. Tejani, D. Li, D.E. Berkowitz, and J.M. Hare Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling Proc. Natl. Acad. Sci. U. S. A. 101 2004 15944 15948 (Pubitemid 39507906)
134. D. Dawson, C.A. Lygate, M.H. Zhang, K. Hulbert, S. Neubauer, and B. Casadei nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction Circulation 112 2005 3729 3737 (Pubitemid 43739513)
135. R.M. Saraiva, K.M. Minhas, S.V. Raju, L.A. Barouch, E. Pitz, K.H. Schuleri, K. Vandegaer, D. Li, and J.M. Hare Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium Circulation 112 2005 3415 3422 (Pubitemid 43739556)
136. X. Loyer, A.M. Gomez, P. Milliez, M. Fernandez-Velasco, P. Vangheluwe, L. Vinet, D. Charue, E. Vaudin, W. Zhang, Y. Sainte-Marie, E. Robidel, I. Marty, B. Mayer, F. Jaisser, J.J. Mercadier, S. Richard, A.M. Shah, J.P. Benitah, J.L. Samuel, and C. Heymes Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling Circulation 117 2008 3187 3198
137. L.A. Barouch, T.P. Cappola, R.W. Harrison, J.K. Crone, E.R. Rodriguez, A.L. Burnett, and J.M. Hare Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice J. Mol. Cell. Cardiol. 35 2003 637 644 (Pubitemid 36677447)
138. W.M. Nauseef Myeloperoxidase biosynthesis by a human promyelocytic leukemia cell line: insight into myeloperoxidase deficiency Blood 67 1986 865 872 (Pubitemid 16116388)
139. W.M. Nauseef, and H.L. Malech Analysis of the peptide subunits of human neutrophil myeloperoxidase Blood 67 1986 1504 1507 (Pubitemid 16080627)
140. S.L. Hazen, and J.W. Heinecke 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima J. Clin. Invest. 99 1997 2075 2081 (Pubitemid 27203762)
141. J.E. Harrison, and J. Schultz Studies on the chlorinating activity of myeloperoxidase J. Biol. Chem. 251 1976 1371 1374
142. S.J. Weiss, S.T. Test, C.M. Eckmann, D. Roos, and S. Regiani Brominating oxidants generated by human eosinophils Science 234 1986 200 203 (Pubitemid 17186098)
143. A. Daugherty, J.L. Dunn, D.L. Rateri, and J.W. Heinecke Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions J. Clin. Invest. 94 1994 437 444 (Pubitemid 24218123)
144. L.J. Hazell, L. Arnold, D. Flowers, G. Waeg, E. Malle, and R. Stocker Presence of hypochlorite-modified proteins in human atherosclerotic lesions J. Clin. Invest. 97 1996 1535 1544 (Pubitemid 26097044)
145. X. Fu, S.Y. Kassim, W.C. Parks, and J.W. Heinecke Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase J. Biol. Chem. 276 2001 41279 41287
146. P. Libby, P.M. Ridker, and A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143 (Pubitemid 34212626)
147. H.M. Abu-Soud, and S.L. Hazen Nitric oxide is a physiological substrate for mammalian peroxidases J. Biol. Chem. 275 2000 37524 37532 (Pubitemid 32004861)
148. J.P. Eiserich, S. Baldus, M.L. Brennan, W. Ma, C. Zhang, A. Tousson, L. Castro, A.J. Lusis, W.M. Nauseef, C.R. White, and B.A. Freeman Myeloperoxidase, a leukocyte-derived vascular NO oxidase Science 296 2002 2391 2394 (Pubitemid 34734213)
149. R. Stocker, A. Huang, E. Jeranian, J.Y. Hou, T.T. Wu, S.R. Thomas, and J.F. Keaney Jr. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism Arterioscler. Thromb. Vasc. Biol. 24 2004 2028 2033 (Pubitemid 39482425)
150. J. Xu, Z. Xie, R. Reece, D. Pimental, and M.H. Zou Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite Arterioscler. Thromb. Vasc. Biol. 26 2006 2688 2695
151. M.L. Brennan, M.M. Anderson, D.M. Shih, X.D. Qu, X. Wang, A.C. Mehta, L.L. Lim, W. Shi, S.L. Hazen, J.S. Jacob, J.R. Crowley, J.W. Heinecke, and A.J. Lusis Increased atherosclerosis in myeloperoxidase-deficient mice J. Clin. Invest. 107 2001 419 430 (Pubitemid 32167988)
152. T.S. McMillen, J.W. Heinecke, and R.C. LeBoeuf Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice Circulation 111 2005 2798 2804 (Pubitemid 40791552)
153. Z. Wang, S.J. Nicholls, E.R. Rodriguez, O. Kummu, S. Horkko, J. Barnard, W.F. Reynolds, E.J. Topol, J.A. DiDonato, and S.L. Hazen Protein carbamylation links inflammation, smoking, uremia and atherogenesis Nat. Med. 13 2007 1176 1184 (Pubitemid 47530630)
154. D. Kutter, P. Devaquet, G. Vanderstocken, J.M. Paulus, V. Marchal, and A. Gothot Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104 2000 10 15
155. R. Zhang, M.L. Brennan, X. Fu, R.J. Aviles, G.L. Pearce, M.S. Penn, E.J. Topol, D.L. Sprecher, and S.L. Hazen Association between myeloperoxidase levels and risk of coronary artery disease JAMA 286 2001 2136 2142 (Pubitemid 34041599)
156. G. Ndrepepa, S. Braun, J. Mehilli, N. von Beckerath, A. Schomig, and A. Kastrati Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes Eur. J. Clin. Invest. 38 2008 90 96 (Pubitemid 351143413)
157. O. Duzguncinar, B. Yavuz, T. Hazirolan, A. Deniz, S.L. Tokgozoglu, D. Akata, and E. Demirpence Plasma myeloperoxidase is related to the severity of coronary artery disease Acta Cardiol. 63 2008 147 152 (Pubitemid 351548698)
158. M.C. Meuwese, E.S. Stroes, S.L. Hazen, J.N. van Miert, J.A. Kuivenhoven, R.G. Schaub, N.J. Wareham, R. Luben, J.J. Kastelein, K.T. Khaw, and S.M. Boekholdt Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study J. Am. Coll. Cardiol. 50 2007 159 165 (Pubitemid 47002189)
159. L. Zheng, B. Nukuna, M.L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P.L. Fox, H. Ischiropoulos, J.D. Smith, M. Kinter, and S.L. Hazen Apolipoprotein A-I is a selective target for myeloperoxidase- catalyzed oxidation and functional impairment in subjects with cardiovascular disease J. Clin. Invest. 114 2004 529 541 (Pubitemid 39572103)
160. C. Bergt, S. Pennathur, X. Fu, J. Byun, K. O'Brien, T.O. McDonald, P. Singh, G.M. Anantharamaiah, A. Chait, J. Brunzell, R.L. Geary, J.F. Oram, and J.W. Heinecke The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport Proc. Natl. Acad. Sci. U. S. A. 101 2004 13032 13037 (Pubitemid 39167578)
161. G. Marsche, P.G. Furtmuller, C. Obinger, W. Sattler, and E. Malle Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro Cardiovasc. Res. 79 2008 187 194 (Pubitemid 351881925)
162. B. Shao, M.N. Oda, J.F. Oram, and J.W. Heinecke Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein Chem. Res. Toxicol. 23 2010 447 454
163. S. Kenmoku, Y. Urano, H. Kojima, and T. Nagano Development of a highly specific rhodamine-based fluorescence probe for hypochlorous acid and its application to real-time imaging of phagocytosis J. Am. Chem. Soc. 129 2007 7313 7318 (Pubitemid 46980809)
164. H. Utsumi, E. Muto, S. Masuda, and A. Hamada In vivo ESR measurement of free radicals in whole mice Biochem. Biophys. Res. Commun. 172 1990 1342 1348
165. H. Utsumi, K. Yasukawa, T. Soeda, K. Yamada, R. Shigemi, T. Yao, and M. Tsuneyoshi Noninvasive mapping of reactive oxygen species by in vivo electron spin resonance spectroscopy in indomethacin-induced gastric ulcers in rats J. Pharmacol. Exp. Ther. 317 2006 228 235
166. R. Zhang, M.L. Brennan, Z. Shen, J.C. MacPherson, D. Schmitt, C.E. Molenda, and S.L. Hazen Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation J. Biol. Chem. 277 2002 46116 46122 (Pubitemid 35417600)
167. D. Sorescu, K. Szocs, and K.K. Griendling NAD(P)H oxidases and their relevance to atherosclerosis Trends Cardiovasc. Med. 11 2001 124 131 (Pubitemid 33070335)
168. J.L. Witztum, and D. Steinberg The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11 2001 93 102 (Pubitemid 33070331)
169. J.L. Mehta, and D.Y. Li Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells Biochem. Biophys. Res. Commun. 248 1998 511 514 (Pubitemid 28404451)
170. S. Yla-Herttuala, W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum, and D. Steinberg Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man J. Clin. Invest. 84 1989 1086 1095 (Pubitemid 19247577)
171. P. Holvoet, A. Mertens, P. Verhamme, K. Bogaerts, G. Beyens, R. Verhaeghe, D. Collen, E. Muls, and F. Van de Werf Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease Arterioscler. Thromb. Vasc. Biol. 21 2001 844 848 (Pubitemid 32448777)
172. P. Holvoet, J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease Circulation 98 1998 1487 1494 (Pubitemid 28481664)
173. S. Toshima, A. Hasegawa, M. Kurabayashi, H. Itabe, T. Takano, J. Sugano, K. Shimamura, J. Kimura, I. Michishita, T. Suzuki, and R. Nagai Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease Arterioscler. Thromb. Vasc. Biol. 20 2000 2243 2247
174. S. Ehara, M. Ueda, T. Naruko, K. Haze, A. Itoh, M. Otsuka, R. Komatsu, T. Matsuo, H. Itabe, T. Takano, Y. Tsukamoto, M. Yoshiyama, K. Takeuchi, J. Yoshikawa, and A.E. Becker Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes Circulation 103 2001 1955 1960 (Pubitemid 32322222)
175. S. Tsimikas, E.S. Brilakis, E.R. Miller, J.P. McConnell, R.J. Lennon, K.S. Kornman, J.L. Witztum, and P.B. Berger Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease N. Engl. J. Med. 353 2005 46 57 (Pubitemid 41007806)
176. T. Inoue, T. Uchida, H. Kamishirado, K. Takayanagi, T. Hayashi, and S. Morooka Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease J. Am. Coll. Cardiol. 37 2001 775 779 (Pubitemid 32202444)
177. T. Miyazaki, K. Shimada, O. Sato, K. Kotani, A. Kume, K. Sumiyoshi, Y. Sato, H. Ohmura, Y. Watanabe, H. Mokuno, and H. Daida Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease Atherosclerosis 179 2005 139 145 (Pubitemid 40249796)
178. J. Hulthe, and B. Fagerberg Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study) Arterioscler. Thromb. Vasc. Biol. 22 2002 1162 1167 (Pubitemid 34764868)
179. C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population Circulation 112 2005 651 657 (Pubitemid 41099043)
180. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins Eur. J. Biochem. 267 2000 4495 4503 (Pubitemid 30461082)
181. S. Sugiyama, Y. Okada, G.K. Sukhova, R. Virmani, J.W. Heinecke, and P. Libby Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes Am. J. Pathol. 158 2001 879 891 (Pubitemid 32221781)
182. J.A. Vita, M.L. Brennan, N. Gokce, S.A. Mann, M. Goormastic, M.H. Shishehbor, M.S. Penn, J.F. Keaney Jr., and S.L. Hazen Serum myeloperoxidase levels independently predict endothelial dysfunction in humans Circulation 110 2004 1134 1139 (Pubitemid 39319014)
183. F.S. Apple, L.A. Pearce, A. Chung, R. Ler, and M.M. Murakami Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome Clin. Chem. 53 2007 874 881 (Pubitemid 46744243)
184. S. Baldus, C. Heeschen, T. Meinertz, A.M. Zeiher, J.P. Eiserich, T. Munzel, M.L. Simoons, and C.W. Hamm Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445 (Pubitemid 37176448)
185. E. Cavusoglu, C. Ruwende, C. Eng, V. Chopra, S. Yanamadala, L.T. Clark, D.J. Pinsky, and J.D. Marmur Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome Am. J. Cardiol. 99 2007 1364 1368 (Pubitemid 46686633)
186. A. Dominguez-Rodriguez, S. Samimi-Fard, P. Abreu-Gonzalez, M.J. Garcia-Gonzalez, and J.C. Kaski Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock Am. J. Cardiol. 101 2008 1537 1540
187. S.Q. Khan, D. Kelly, P. Quinn, J.E. Davies, and L.L. Ng Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction Heart 93 2007 826 831 (Pubitemid 46998982)
188. T.J. Mocatta, A.P. Pilbrow, V.A. Cameron, R. Senthilmohan, C.M. Frampton, A.M. Richards, and C.C. Winterbourn Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction J. Am. Coll. Cardiol. 49 2007 1993 2000 (Pubitemid 46734639)
189. D.A. Morrow, M.S. Sabatine, M.L. Brennan, J.A. de Lemos, S.A. Murphy, C.T. Ruff, N. Rifai, C.P. Cannon, and S.L. Hazen Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18 Eur. Heart J. 29 2008 1096 1102 (Pubitemid 351844877)
190. A. Stefanescu, S. Braun, G. Ndrepepa, T. Koppara, H. Pavaci, J. Mehilli, A. Schomig, and A. Kastrati Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease Am. Heart J. 155 2008 356 360
191. M.L. Brennan, M.S. Penn, F. Van Lente, V. Nambi, M.H. Shishehbor, R.J. Aviles, M. Goormastic, M.L. Pepoy, E.S. McErlean, E.J. Topol, S.E. Nissen, and S.L. Hazen Prognostic value of myeloperoxidase in patients with chest pain N. Engl. J. Med. 349 2003 1595 1604 (Pubitemid 37288567)
192. B. Nikpoor, G. Turecki, C. Fournier, P. Theroux, and G.A. Rouleau A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians Am. Heart J. 142 2001 336 339 (Pubitemid 32706293)
193. F.W. Asselbergs, W.F. Reynolds, J.W. Cohen-Tervaert, G.A. Jessurun, and R.A. Tio Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease Am. J. Med. 116 2004 429 430 (Pubitemid 38299491)
194. S. Baldus, V. Rudolph, M. Roiss, W.D. Ito, T.K. Rudolph, J.P. Eiserich, K. Sydow, D. Lau, K. Szocs, A. Klinke, L. Kubala, L. Berglund, S. Schrepfer, T. Deuse, M. Haddad, T. Risius, H. Klemm, H.C. Reichenspurner, T. Meinertz, and T. Heitzer Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase Circulation 113 2006 1871 1878 (Pubitemid 43739399)
195. C. Leculier, N. Couprie, P. Adeleine, P. Leitienne, A. Francina, and M. Richard The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes Thromb. Res. 69 1993 519 531 (Pubitemid 23106438)
196. G. de Gaetano, C. Cerletti, and V. Evangelista Recent advances in platelet-polymorphonuclear leukocyte interaction Haemostasis 29 1999 41 49 (Pubitemid 29446371)
197. J. Shih, S.A. Datwyler, S.C. Hsu, M.S. Matias, D.P. Pacenti, C. Lueders, C. Mueller, O. Danne, and M. Mockel Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations Clin. Chem. 54 2008 1076 1079 (Pubitemid 351793416)
198. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts II A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. U. S. A. 87 1990 9383 9387 (Pubitemid 120030630)
199. S.M. Lynch, J.D. Morrow, L.J. Roberts II, and B. Frei Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro J. Clin. Invest. 93 1994 998 1004 (Pubitemid 24087149)
200. J.D. Morrow, and L.J. Roberts The isoprostanes: unique bioactive products of lipid peroxidation Prog. Lipid Res. 36 1997 1 21 (Pubitemid 27387112)
201. J.D. Morrow Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans Arterioscler. Thromb. Vasc. Biol. 25 2005 279 286 (Pubitemid 40189146)
202. D. Pratico, J. Rokach, J. Lawson, and G.A. FitzGerald F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases Chem. Phys. Lipids 128 2004 165 171 (Pubitemid 38167385)
203. J.A. Awad, L.J. Roberts II, R.F. Burk, and J.D. Morrow Isoprostanes-prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage Gastroenterol. Clin. North Am. 25 1996 409 427 (Pubitemid 26161892)
204. L.J. Roberts II, and J.D. Morrow The generation and actions of isoprostanes Biochim. Biophys. Acta 1345 1997 121 135 (Pubitemid 27138414)
205. D. Pratico, and G.A. FitzGerald Generation of 8-epiprostaglandin F2alpha by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2 J. Biol. Chem. 271 1996 8919 8924
206. D. Pratico, L. Iuliano, A. Mauriello, L. Spagnoli, J.A. Lawson, J. Rokach, J. Maclouf, F. Violi, and G.A. FitzGerald Localization of distinct F2-isoprostanes in human atherosclerotic lesions J. Clin. Invest. 100 1997 2028 2034 (Pubitemid 27459357)
207. Z. Mallat, T. Nakamura, J. Ohan, G. Leseche, A. Tedgui, J. Maclouf, and R.C. Murphy The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis J. Clin. Invest. 103 1999 421 427 (Pubitemid 29069993)
208. C. Vassalle, N. Botto, M.G. Andreassi, S. Berti, and A. Biagini Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease Coron. Artery Dis. 14 2003 213 218 (Pubitemid 36578048)
209. E. Schwedhelm, A. Bartling, H. Lenzen, D. Tsikas, R. Maas, J. Brummer, F.M. Gutzki, J. Berger, J.C. Frolich, and R.H. Boger Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study Circulation 109 2004 843 848 (Pubitemid 38252735)
210. F. Cipollone, G. Ciabattoni, P. Patrignani, M. Pasquale, D. Di Gregorio, T. Bucciarelli, G. Davi, F. Cuccurullo, and C. Patrono Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina Circulation 102 2000 1007 1013 (Pubitemid 30657517)
211. 2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome Am. J. Cardiol. 104 2009 638 643
212. M.P. Reilly, N. Delanty, L. Roy, J. Rokach, P.O. Callaghan, P. Crean, J.A. Lawson, and G.A. FitzGerald Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans Circulation 96 1997 3314 3320 (Pubitemid 27513400)
213. Z. Mallat, I. Philip, M. Lebret, D. Chatel, J. Maclouf, and A. Tedgui Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure Circulation 97 1998 1536 1539 (Pubitemid 28186180)
214. M.C. Polidori, D. Pratico, K. Savino, J. Rokach, W. Stahl, and P. Mecocci Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity J. Card. Fail. 10 2004 334 338 (Pubitemid 39092686)
215. J.F. Keaney Jr. Circulating biomarkers in acute coronary syndromes: something different or more of the same? Circulation 112 2005 778 780 (Pubitemid 41170060)
216. J.A. Vita, J.F. Keaney Jr., K.E. Raby, J.D. Morrow, J.E. Freedman, S. Lynch, S.N. Koulouris, B.R. Hankin, and B. Frei Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome J. Am. Coll. Cardiol. 31 1998 980 986 (Pubitemid 28212496)
217. R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, and B.N. Ames Bilirubin is an antioxidant of possible physiological importance Science 235 1987 1043 1046 (Pubitemid 17049750)
218. H.A. Schwertner, and J.R. Fischer Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease Atherosclerosis 150 2000 381 387 (Pubitemid 30336550)
219. M. Mayer Association of serum bilirubin concentration with risk of coronary artery disease Clin. Chem. 46 2000 1723 1727
220. M. Madhavan, W.A. Wattigney, S.R. Srinivasan, and G.S. Berenson Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults Atherosclerosis 131 1997 107 113 (Pubitemid 27240103)
221. H. Shimomura, H. Ogawa, K. Takazoe, H. Soejima, S. Miyamoto, T. Sakamoto, H. Kawano, H. Suefuji, H. Nishikawa, H. Arai, J. Hokamaki, I. Kajiwara, K. Kugiyama, and M. Yoshimura Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events Am. J. Cardiol. 90 2002 108 111 (Pubitemid 34775116)
222. J. Hokamaki, H. Kawano, M. Yoshimura, H. Soejima, S. Miyamoto, I. Kajiwara, S. Kojima, T. Sakamoto, S. Sugiyama, N. Hirai, H. Shimomura, Y. Nagayoshi, K. Tsujita, I. Shioji, S. Sasaki, and H. Ogawa Urinary biopyrrins levels are elevated in relation to severity of heart failure J. Am. Coll. Cardiol. 43 2004 1880 1885 (Pubitemid 38622530)
223. S. Blankenberg, H.J. Rupprecht, C. Bickel, M. Torzewski, G. Hafner, L. Tiret, M. Smieja, F. Cambien, J. Meyer, and K.J. Lackner Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease N. Engl. J. Med. 349 2003 1605 1613 (Pubitemid 37288568)
224. Y. Nagayoshi, H. Kawano, J. Hokamaki, S. Miyamoto, S. Kojima, H. Shimomura, K. Tsujita, T. Sakamoto, M. Yoshimura, and H. Ogawa Urinary 8-hydroxy-2'-deoxyguanosine levels increase after reperfusion in acute myocardial infarction and may predict subsequent cardiac events Am. J. Cardiol. 95 2005 514 517 (Pubitemid 40247553)
225. Y. Kono, K. Nakamura, H. Kimura, N. Nishii, A. Watanabe, K. Banba, A. Miura, S. Nagase, S. Sakuragi, K.F. Kusano, H. Matsubara, and T. Ohe Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure Circ. J. 70 2006 1001 1005 (Pubitemid 44161736)
226. D.G. Hackam, and S.S. Anand Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence JAMA 290 2003 932 940 (Pubitemid 37430466)
227. M.L. Simoons, P.W. Serruys, M. van den Brand, J. Res, F.W. Verheugt, X.H. Krauss, W.J. Remme, F. Bar, C. de Zwaan, and A. van der Laarse Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival J. Am. Coll. Cardiol. 7 1986 717 728 (Pubitemid 16107115)
228. F.H. Sheehan, R. Doerr, W.G. Schmidt, E.L. Bolson, R. Uebis, R. von Essen, S. Effert, and H.T. Dodge Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival J. Am. Coll. Cardiol. 12 1988 289 300
229. H.D. White, R.M. Norris, M.A. Brown, M. Takayama, A. Maslowski, N.M. Bass, J.A. Ormiston, and T. Whitlock Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction N. Engl. J. Med. 317 1987 850 855 (Pubitemid 17156728)
230. R. Bolli, M.O. Jeroudi, B.S. Patel, C.M. DuBose, E.K. Lai, R. Roberts, and P.B. McCay Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog Proc. Natl. Acad. Sci. U. S. A. 86 1989 4695 4699 (Pubitemid 19164616)
231. S. Verma, and T.J. Anderson Fundamentals of endothelial function for the clinical cardiologist Circulation 105 2002 546 549 (Pubitemid 34123425)
232. S. Toyokuni Reactive oxygen species-induced molecular damage and its application in pathology Pathol. Int. 49 1999 91 102 (Pubitemid 29133467)
233. M. Chevion, Y.D. Jiang, R. Harel, E. Berenshtein, G. Uretzky, and N. Kitrossky Copper and iron are mobilized following myocardial-ischemia-possible predictive criteria for tissue-injury Proc. Natl. Acad. Sci. U. S. A. 90 1993 1102 1106 (Pubitemid 23053959)
234. G. Minotti, and S.D. Aust Redox cycling of iron and lipid peroxidation Lipids 27 1992 219 226
235. G. Minotti, and S.D. Aust The role of iron in the initiation of lipid peroxidation Chem. Phys. Lipids 44 1987 191 208
236. H. Kappus Lipid peroxidation: mechanisms, analysis, enzymology and biological relevance H. Sies, Oxidative Stress 1985 Academic Press London 273 310
237. B.E. Hedlund, and P.E. Hallaway High-dose systemic iron chelation attenuates reperfusion injury Biochem. Soc. Trans. 21 1993 340 343 (Pubitemid 23167919)
238. 2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion Am. J. Physiol. Heart Circ. Physiol. 290 2006 H2024 H2034
239. R. Ferreira, M. Burgos, J. Milei, S. Llesuy, L. Molteni, H. Hourquebie, and A. Boveris Effect of supplementing cardioplegic solution with deferoxamine on reperfused human myocardium J. Thorac. Cardiovasc. Surg. 100 1990 708 714
240. I.A. Paraskevaidis, E.K. Iliodromitis, D. Vlahakos, D.P. Tsiapras, A. Nikolaidis, A. Marathias, A. Michalis, and D.T. Kremastinos Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance Eur. Heart J. 26 2005 263 270 (Pubitemid 40227432)
241. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters Cerebrovasc. Dis. 15 2003 222 229
242. K. Tsujita, H. Shimomura, H. Kawano, J. Hokamaki, M. Fukuda, T. Yamashita, S. Hida, Y. Nakamura, Y. Nagayoshi, T. Sakamoto, M. Yoshimura, H. Arai, and H. Ogawa Effects of edaravone on reperfusion injury in patients with acute myocardial infarction Am. J. Cardiol. 94 2004 481 484 (Pubitemid 39120000)
243. K. Tsujita, H. Shimomura, K. Kaikita, H. Kawano, J. Hokamaki, Y. Nagayoshi, T. Yamashita, M. Fukuda, Y. Nakamura, T. Sakamoto, M. Yoshimura, and H. Ogawa Long-term efficacy of edaravone in patients with acute myocardial infarction Circ. J. 70 2006 832 837 (Pubitemid 43979118)
244. W.A. Zamboni, A.C. Roth, R.C. Russell, and E.C. Smoot The effect of hyperbaric oxygen on reperfusion of ischemic axial skin flaps: a laser Doppler analysis Ann. Plast. Surg. 28 1992 339 341
245. S.R. Thom, and M.E. Elbuken Oxygen-dependent antagonism of lipid peroxidation Free Radic. Biol. Med. 10 1991 413 426 (Pubitemid 121003240)
246. W.W. O'Neill, J.L. Martin, S.R. Dixon, A.L. Bartorelli, D. Trabattoni, P.V. Oemrawsingh, D.E. Atsma, M. Chang, W. Marquardt, J.K. Oh, M.W. Krucoff, R.J. Gibbons, and J.R. Spears Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention J. Am. Coll. Cardiol. 50 2007 397 405 (Pubitemid 47088128)
247. G.W. Stone, J.L. Martin, M.J. de Boer, M. Margheri, E. Bramucci, J.C. Blankenship, D.C. Metzger, R.J. Gibbons, B.S. Lindsay, B.H. Weiner, A.J. Lansky, M.W. Krucoff, M. Fahy, and W.J. Boscardin Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction Circ. Cardiovasc. Interv. 2 2009 366 375
248. R. Bolli, L. Becker, G. Gross, R. Mentzer Jr., D. Balshaw, and D.A. Lathrop Myocardial protection at a crossroads: the need for translation into clinical therapy Circ. Res. 95 2004 125 134 (Pubitemid 38988678)
249. R.O. Cannon III Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction Nat. Clin. Pract. Cardiovasc. Med. 2 2005 88 94 (Pubitemid 40778860)
250. D.B. Sawyer, D.A. Siwik, L. Xiao, D.R. Pimentel, K. Singh, and W.S. Colucci Role of oxidative stress in myocardial hypertrophy and failure J. Mol. Cell. Cardiol. 34 2002 379 388 (Pubitemid 37163454)
251. P. Korantzopoulos, D. Galaris, D. Papaioannides, and K. Siogas The possible role of oxidative stress in heart failure and the potential of antioxidant intervention Med. Sci. Monit. 9 2003 RA120 RA125
252. J.L. Zweier, B.K. Rayburn, J.T. Flaherty, and M.L. Weisfeldt Recombinant superoxide dismutase reduces oxygen free radical concentrations in reperfused myocardium J. Clin. Invest. 80 1987 1728 1734 (Pubitemid 18007148)
253. S. Rajagopalan, P.M. Politi, B.K. Sinha, and C.E. Myers Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity Cancer Res. 48 1988 4766 4769
254. J. Vaage, M. Antonelli, M. Bufi, O. Irtun, R.A. DeBlasi, G.G. Corbucci, A. Gasparetto, and A.G. Semb Exogenous reactive oxygen species deplete the isolated rat heart of antioxidants Free Radic. Biol. Med. 22 1997 85 92
255. A.K. Dhalla, and P.K. Singal Antioxidant changes in hypertrophied and failing guinea pig hearts Am. J. Physiol. 266 1994 H1280 H1285
256. M.F. Hill, and P.K. Singal Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction Circulation 96 1997 2414 2420 (Pubitemid 27425850)
257. R.M. Lebovitz, H. Zhang, H. Vogel, J. Cartwright Jr., L. Dionne, N. Lu, S. Huang, and M.M. Matzuk Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice Proc. Natl. Acad. Sci. U. S. A. 93 1996 9782 9787 (Pubitemid 26296686)
258. N. Khaper, and P.K. Singal Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats J. Am. Coll. Cardiol. 29 1997 856 861 (Pubitemid 27128261)
259. A.K. Dhalla, M.F. Hill, and P.K. Singal Role of oxidative stress in transition of hypertrophy to heart failure J. Am. Coll. Cardiol. 28 1996 506 514 (Pubitemid 26274350)
260. T. Shiomi, H. Tsutsui, H. Matsusaka, K. Murakami, S. Hayashidani, M. Ikeuchi, J. Wen, T. Kubota, H. Utsumi, and A. Takeshita Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice Circulation 109 2004 544 549 (Pubitemid 38168520)
261. G. Wang, T. Hamid, R.J. Keith, G. Zhou, C.R. Partridge, X. Xiang, J.R. Kingery, R.K. Lewis, Q. Li, D.G. Rokosh, R. Ford, F.G. Spinale, D.W. Riggs, S. Srivastava, A. Bhatnagar, R. Bolli, and S.D. Prabhu Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart Circulation 121 2010 1912 1925
262. T. Li, and P.K. Singal Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol Circulation 102 2000 2105 2110
263. R. Bolli, M.O. Jeroudi, B.S. Patel, O.I. Aruoma, B. Halliwell, E.K. Lai, and P.B. McCay Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury Circ. Res. 65 1989 607 622 (Pubitemid 19226437)
264. G.J. Gross, S.T. O'Rourke, L.R. Pelc, and D.C. Warltier Myocardial and endothelial dysfunction after multiple, brief coronary occlusions: role of oxygen radicals Am. J. Physiol. 263 1992 H1703 H1709
265. F. Qin, J. Shite, and C.S. Liang Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways Am. J. Physiol. Heart Circ. Physiol. 285 2003 H822 H832
266. R. Nakamura, K. Egashira, Y. Machida, S. Hayashidani, M. Takeya, H. Utsumi, H. Tsutsui, and A. Takeshita Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation Circulation 106 2002 362 367 (Pubitemid 34778962)
267. Y.T. Sia, T.G. Parker, P. Liu, J.N. Tsoporis, A. Adam, and J.L. Rouleau Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression J. Am. Coll. Cardiol. 39 2002 148 156 (Pubitemid 34059875)
268. E.M. Redout, A. van der Toorn, M.J. Zuidwijk, C.W. van de Kolk, C.J. van Echteld, R.J. Musters, C. van Hardeveld, W.J. Paulus, and W.S. Simonides Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure Am. J. Physiol. Heart Circ. Physiol. 298 2010 H1038 H1047
269. M. Hamblin, H.M. Smith, and M.F. Hill Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione J. Card. Fail. 13 2007 884 892 (Pubitemid 350198931)
270. K.M. Minhas, R.M. Saraiva, K.H. Schuleri, S. Lehrke, M. Zheng, A.P. Saliaris, C.E. Berry, L.A. Barouch, K.M. Vandegaer, D. Li, and J.M. Hare Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy Circ. Res. 98 2006 271 279
271. C. Heymes, J.K. Bendall, P. Ratajczak, A.C. Cave, J.L. Samuel, G. Hasenfuss, and A.M. Shah Increased myocardial NADPH oxidase activity in human heart failure J. Am. Coll. Cardiol. 41 2003 2164 2171 (Pubitemid 36724261)
272. F. Sam, D.L. Kerstetter, D.R. Pimental, S. Mulukutla, A. Tabaee, M.R. Bristow, W.S. Colucci, and D.B. Sawyer Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium J. Card. Fail. 11 2005 473 480
273. S.D. Anker, W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C.H. Davos, M. Cicoira, W. Shamim, M. Kemp, R. Segal, K.J. Osterziel, F. Leyva, R. Hetzer, P. Ponikowski, and A.J. Coats Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging Circulation 107 2003 1991 1997 (Pubitemid 36506072)
274. E. Krishnan Hyperuricemia and incident heart failure Circ. Heart Fail. 2 2009 556 562
275. M.I. Ahmed, J.D. Gladden, S.H. Litovsky, S.G. Lloyd, H. Gupta, S. Inusah, T. Denney Jr., P. Powell, D.C. McGiffin, and L.J. Dell'Italia Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction > 60% J. Am. Coll. Cardiol. 55 2010 671 679
276. T.P. Cappola, D.A. Kass, G.S. Nelson, R.D. Berger, G.O. Rosas, Z.A. Kobeissi, E. Marban, and J.M. Hare Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy Circulation 104 2001 2407 2411 (Pubitemid 33108372)
277. C.A. Farquharson, R. Butler, A. Hill, J.J. Belch, and A.D. Struthers Allopurinol improves endothelial dysfunction in chronic heart failure Circulation 106 2002 221 226 (Pubitemid 34761303)
278. J. George, E. Carr, J. Davies, J.J. Belch, and A. Struthers High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid Circulation 114 2006 2508 2516 (Pubitemid 44901524)
279. J.M. Hare, B. Mangal, J. Brown, C. Fisher Jr., R. Freudenberger, W.S. Colucci, D.L. Mann, P. Liu, M.M. Givertz, and R.P. Schwarz Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study J. Am. Coll. Cardiol. 51 2008 2301 2309 (Pubitemid 351783365)
280. J. George, and A. Struthers The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose J. Am. Coll. Cardiol. 53 2009 2405
281. N. Gokce, J.F. Keaney Jr., B. Frei, M. Holbrook, M. Olesiak, B.J. Zachariah, C. Leeuwenburgh, J.W. Heinecke, and J.A. Vita Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease Circulation 99 1999 3234 3240 (Pubitemid 29293432)
282. K. Kugiyama, T. Motoyama, O. Hirashima, M. Ohgushi, H. Soejima, K. Misumi, H. Kawano, Y. Miyao, M. Yoshimura, H. Ogawa, T. Matsumura, S. Sugiyama, and H. Yasue Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina J. Am. Coll. Cardiol. 32 1998 103 109 (Pubitemid 28351049)
283. T. Motoyama, H. Kawano, K. Kugiyama, O. Hirashima, M. Ohgushi, R. Tsunoda, Y. Moriyama, Y. Miyao, M. Yoshimura, H. Ogawa, and H. Yasue Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina J. Am. Coll. Cardiol. 32 1998 1672 1679 (Pubitemid 28545207)
284. M.E. Keith, K.N. Jeejeebhoy, A. Langer, R. Kurian, A. Barr, B. O'Kelly, and M.J. Sole A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure Am. J. Clin. Nutr. 73 2001 219 224 (Pubitemid 32109849)
285. K.A. Weant, and K.M. Smith The role of coenzyme Q10 in heart failure Ann. Pharmacother. 39 2005 1522 1526 (Pubitemid 41197135)
286. E.A. Kirk, M.C. Dinauer, H. Rosen, A. Chait, J.W. Heinecke, and R.C. LeBoeuf Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice Arterioscler. Thromb. Vasc. Biol. 20 2000 1529 1535 (Pubitemid 30353884)
287. E. Takimoto, H.C. Champion, M. Li, S. Ren, E.R. Rodriguez, B. Tavazzi, G. Lazzarino, N. Paolocci, K.L. Gabrielson, Y. Wang, and D.A. Kass Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load J. Clin. Invest. 115 2005 1221 1231 (Pubitemid 40629040)
288. U. Flogel, U.K. Decking, A. Godecke, and J. Schrader Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart: a study in endothelial NO synthase knockout mice J. Mol. Cell. Cardiol. 31 1999 827 836 (Pubitemid 29201552)
289. R.L. Hannan, M.C. John, P.C. Kouretas, B.D. Hack, G.P. Matherne, and V.E. Laubach Deletion of endothelial nitric oxide synthase exacerbates myocardial stunning in an isolated mouse heart model J. Surg. Res. 93 2000 127 132
290. S.P. Jones, W.G. Girod, A.J. Palazzo, D.N. Granger, M.B. Grisham, D. Jourd'Heuil, P.L. Huang, and D.J. Lefer Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase Am. J. Physiol. 276 1999 H1567 H1573
291. B.R. Sharp, S.P. Jones, D.M. Rimmer, and D.J. Lefer Differential response to myocardial reperfusion injury in eNOS-deficient mice Am. J. Physiol. Heart Circ. Physiol. 282 2002 H2422 H2426
292. J. Heger, A. Godecke, U. Flogel, M.W. Merx, A. Molojavyi, W.N. Kuhn-Velten, and J. Schrader Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction Circ. Res. 90 2002 93 99 (Pubitemid 34074614)
293. M.B. West, G. Rokosh, D. Obal, M. Velayutham, Y.T. Xuan, B.G. Hill, R.J. Keith, J. Schrader, Y. Guo, D.J. Conklin, S.D. Prabhu, J.L. Zweier, R. Bolli, and A. Bhatnagar Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition Circulation 118 2008 1970 1978
294. A. Godecke, A. Molojavyi, J. Heger, U. Flogel, Z. Ding, C. Jacoby, and J. Schrader Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress J. Biol. Chem. 278 2003 21761 21766 (Pubitemid 36792579)
295. N. Vasilyev, T. Williams, M.L. Brennan, S. Unzek, X. Zhou, J.W. Heinecke, D.R. Spitz, E.J. Topol, S.L. Hazen, and M.S. Penn Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction Circulation 112 2005 2812 2820 (Pubitemid 41643823)
296. A.T. Askari, M.L. Brennan, X. Zhou, J. Drinko, A. Morehead, J.D. Thomas, E.J. Topol, S.L. Hazen, and M.S. Penn Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction J. Exp. Med. 197 2003 615 624 (Pubitemid 36314656)
297. T. Tsutsui, T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, M. Ohnishi, and M. Kinoshita Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure J. Am. Coll. Cardiol. 39 2002 957 962 (Pubitemid 34234116)
298. J.W. Stephens, D.R. Gable, S.J. Hurel, G.J. Miller, J.A. Cooper, and S.E. Humphries Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males Clin. Chem. 52 2006 446 452